Novateor Research Laboratories Ltd
₹ 32.6
-18.60%
09 Nov
- close price
About
Incorporated in 2011, Novateor Research Laboratories Ltd is in the business of Oral Care and Personal Care products.[1]
Key Points
- Market Cap ₹ 19.7 Cr.
- Current Price ₹ 32.6
- High / Low ₹ 48.0 / 20.1
- Stock P/E 197
- Book Value ₹ 19.0
- Dividend Yield 0.00 %
- ROCE 1.67 %
- ROE 0.91 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 0.72% over last 3 years.
- Company has high debtors of 269 days.
- Promoter holding has decreased over last 3 years: -10.1%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Half Yearly Results
Figures in Rs. Crores
Upcoming result date: 14 November 2026
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.02 | 0.10 | 0.14 | 0.09 | 0.41 | 0.39 | 0.19 | 0.74 | 1.26 | 1.21 | 2.78 | 3.83 | |
| Sales growth | -33.33% | +400.00% | +40.00% | -35.71% | +355.56% | -4.88% | -51.28% | +289.47% | +70.27% | -3.97% | +129.75% | +37.77% |
| 0.02 | 0.11 | 0.08 | 0.04 | 0.13 | 0.53 | 0.52 | 0.92 | 1.60 | 1.54 | 2.92 | 3.93 | |
| Operating Profit | 0.00 | -0.01 | 0.06 | 0.05 | 0.28 | -0.14 | -0.33 | -0.18 | -0.34 | -0.33 | -0.14 | -0.10 |
| OPM % | 0.00% | -10.00% | 42.86% | 55.56% | 68.29% | -35.90% | -173.68% | -24.32% | -26.98% | -27.27% | -5.04% | -2.61% |
| 0.00 | 0.01 | 0.02 | 0.03 | 0.11 | 0.27 | 0.44 | 0.01 | 0.49 | 0.49 | 0.48 | 0.49 | |
| Interest | 0.00 | 0.00 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.02 | 0.03 | 0.07 | 0.09 |
| Depreciation | 0.00 | 0.00 | 0.07 | 0.07 | 0.10 | 0.10 | 0.10 | 0.09 | 0.09 | 0.08 | 0.16 | 0.19 |
| Profit before tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 | 0.02 | 0.01 | -0.26 | 0.04 | 0.05 | 0.11 | 0.11 |
| Tax % | 24.14% | 150.00% | 0.00% | -11.54% | 0.00% | 40.00% | 27.27% | 18.18% | ||||
| 0.00 | 0.00 | 0.00 | 0.00 | 0.22 | -0.01 | 0.01 | -0.23 | 0.04 | 0.03 | 0.08 | 0.10 | |
| EPS in Rs | 0.00 | 0.00 | 0.00 | 0.00 | 0.74 | -0.02 | 0.02 | -0.48 | 0.08 | 0.06 | 0.17 | 0.17 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 44% |
| 5 Years: | 82% |
| 3 Years: | 45% |
| TTM: | 38% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 58% |
| 3 Years: | 36% |
| TTM: | 25% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 29% |
| 3 Years: | -1% |
| 1 Year: | 25% |
| Return on Equity | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 1% |
| 3 Years: | 1% |
| Last Year: | 1% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.05 | 0.05 | 0.05 | 0.05 | 2.96 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 4.83 | 6.05 |
| Reserves | 0.88 | 0.88 | 0.88 | 0.88 | 1.11 | 3.73 | 3.74 | 3.01 | 3.04 | 3.93 | 5.71 | 5.45 |
| 0.75 | 0.76 | 0.87 | 0.82 | 0.01 | 0.00 | 0.24 | 0.24 | 0.84 | 1.11 | 0.91 | 1.03 | |
| 0.11 | 0.15 | 0.10 | 0.09 | 0.24 | 0.23 | 0.17 | 0.06 | 0.24 | 0.59 | 1.16 | 1.74 | |
| Total Liabilities | 1.79 | 1.84 | 1.90 | 1.84 | 4.32 | 8.79 | 8.98 | 8.14 | 8.95 | 10.46 | 12.61 | 14.27 |
| 1.59 | 1.64 | 1.66 | 1.59 | 3.55 | 3.45 | 3.36 | 1.94 | 1.78 | 2.43 | 3.41 | 3.24 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.43 | 0.44 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| 0.19 | 0.19 | 0.23 | 0.24 | 0.76 | 5.33 | 5.61 | 6.19 | 6.73 | 7.58 | 9.19 | 11.02 | |
| Total Assets | 1.79 | 1.84 | 1.90 | 1.84 | 4.32 | 8.79 | 8.98 | 8.14 | 8.95 | 10.46 | 12.61 | 14.27 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.01 | 0.05 | -0.07 | -3.42 | -0.27 | -0.97 | -0.97 | -0.98 | -1.03 | -0.18 | |
| 0.00 | 0.00 | -0.01 | 0.00 | -1.96 | -0.10 | -0.09 | 0.91 | 0.13 | -0.25 | -0.22 | -0.50 | |
| 0.00 | 0.00 | 0.00 | -0.03 | 2.03 | 4.18 | 0.32 | -0.13 | 0.58 | 1.10 | 1.43 | 0.89 | |
| Net Cash Flow | 0.00 | 0.00 | -0.01 | 0.02 | 0.00 | 0.67 | -0.04 | -0.18 | -0.26 | -0.13 | 0.18 | 0.20 |
| Free Cash Flow | 0.00 | 0.00 | 0.00 | 0.05 | -2.03 | -3.52 | -0.36 | -0.06 | -1.33 | -1.72 | -1.73 | -0.20 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 0% | 17% | 100% | 0% | 2,443% | 82% | 539% | 285% | 297% | 736% | 180% |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 365.00 | 219.00 | 182.50 | 243.33 | 133.54 | 233.97 | 384.21 | 212.09 | 202.78 | 337.85 | 271.78 | 268.75 |
| Inventory Days | 4,380.00 | 438.00 | 1,460.00 | 2,737.50 | 6,448.33 | 700.80 | 851.67 | 344.34 | 215.16 | 268.95 | 151.10 | 152.08 |
| Days Payable | 1,460.00 | 292.00 | 730.00 | 1,095.00 | 1,460.00 | 14.60 | 104.29 | 20.66 | 61.47 | 207.47 | 176.61 | 208.57 |
| Cash Conversion Cycle | 3,285.00 | 365.00 | 912.50 | 1,885.83 | 5,121.87 | 920.17 | 1,131.59 | 535.77 | 356.46 | 399.32 | 246.27 | 212.26 |
| Working Capital Days | 1,277.50 | 109.50 | 286.79 | 527.22 | 462.93 | 4,117.95 | 9,067.37 | 2,747.36 | 1,604.84 | 1,879.30 | 950.58 | 770.98 |
| ROCE % | 0.00% | 0.00% | 0.57% | 0.56% | 9.95% | 0.47% | 0.12% | 2.49% | 0.71% | 0.86% | 1.69% | 1.67% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|
| Number of Permanent Employees employees |
|
|||||||
| Number of Product Categories in Portfolio categories |
||||||||
Requires Premium
Requires Premium
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for Adoption Of Unaudited Financial Results For The Half Year Ended On September 30, 2026
- Board meeting on 14 Nov 2026 to approve half-year unaudited results; trading window closed from 1 Oct 2026.
-
Announcement under Regulation 30 (LODR)-Memorandum of Understanding /Agreements
- Novateor signed 3-year exclusive supply agreement with Pidilite for oral-care products on Oct. 15, 2026.
-
Non Applicability Of Disclosure Under Regulation 23(9) Of SEBI (LODR) Regulations, 2015
- SME-listed Novateor says Regulation 23(9) related party disclosures are not applicable for half-year ended September 30, 2026.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
- Submitted Regulation 74(5) certificate for quarter ended September 30, 2026.
- Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Annual reports
-
Annual Report 2026
from bse
-
Annual Report 2025
from bse
-
Annual Report 2024
from bse
-
Annual Report 2023
from bse
-
Annual Report 2022
from bse
-
Annual Report 2021
from bse
-
Annual Report 2020
from bse
Business Overview:[1]
a) NRLL develops FDA-approved personal care products for clinical and commercial purposes.
b) It’s current Teeth Whitening products
are sold under the brand name Smile Shine
c) The company manufactures 3 different variants of Teeth Whitening Strips, Teeth White
Toothpaste and brush, Kids Toothpaste and
tongue cleaner, Teeth Whitening Gel, Power
Brush.
d) It intends to expand its business in cosmetics, various health care pharma products in the near future
e) The company’s customer base consists of Dentists as well as Cosmetic Parlors